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Children with autism spectrum disorders (ASD) have several risk factors for low bone mineral density.The gluten-free, casein-free
(GFCF) diet is a complementary therapy sometimes used in ASD that raises concerns for the adequacy of calcium and vitamin
D intake. This study evaluated the prescribing practices of calcium and vitamin D supplements and the practice of checking 25-
hydroxy vitamin D (25(OH)D) levels by providers in 100 children with ASD, 50 of whomwere on the GFCF diet. Fifty-two percent
and 46%of children on theGFCFdiet were on some formof vitaminD and calcium supplements, respectively, compared to 18% and
14% of those not on this diet. Twenty-four percent of children in the GFCF group had a documented 25(OH)D level compared to
none in the non-GFCF group.The data highlight a gap in calcium and vitaminD supplement prescribing practices among providers
caring for children with ASD as well as a gap in the practice of checking 25(OH)D levels.
1. Introduction
Autism spectrumdisorder (ASD) is a developmental disorder
with various degrees of severity that can cause significant
social, communication, and behavioral challenges. Data from
the Center for Disease Control’s Autism and Developmental
Disabilities Monitoring (ADDM) Network show that the
estimated number of children identified with ASD continues
to rise in the United States with 1 in 68 children estimated to
have an ASD in 2014 [1]. Peak bonemass, an important deter-
minant of future bone health, is achieved by early adulthood,
and the childhood and adolescent years are a critical period
for bone accrual. Factors that affect bone accrual in childhood
include genetics, nutritional status, calcium and vitamin D
intake, weight bearing activity, hormonal alterations, and
the use of certain medications [2]. Children with ASD have
several risk factors that could potentially contribute to low
bone mineral density (BMD), including decreased exercise,
restricted diets, and use of medications that are deleterious
to bone health. Nutritional status is a potentially modifiable
factor and is very relevant to bone accrual in children.
In the absence of curative options for the management of
ASD, many parents turn towards alternative therapies and
the gluten-free, casein-free (GFCF) diet is one such dietary
therapy. A systematic review of studies published from 1970
to 2014 related to the GFCF diet in ASD patients showed that
the evidence on this topic is currently limited and weak [3].
However, this diet continues to be used by childrenwithASD,
largely based on anecdotal evidence for improvement.
In the US, most of one’s dietary intake of calcium comes
from dairy products while the dietary intake of vitamin D is
derived from fortified foods such as milk and milk products
with vitamin D [4]. In addition, children derive vitamin D
through sun exposure. A diet limited in dairy products such
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as the GFCF diet raises concerns for the adequacy of calcium
and vitamin D intake in the absence of supplementation.
Additionally, outdoor physical activity and sun exposuremay
be limited in children with ASD compared to their typical
peers limiting their endogenous vitaminDproduction,which
is already limited in the northern latitudes. A low serum
phosphorus level could be one of the initial signs of mild
vitamin D deficiency that occurs even before serum calcium
level falls [5].
Other risk factors for low BMD in children with ASD
include reduced weight bearing activity and high rates of
comorbid neurologic and psychiatric illnesses, including
epilepsy andmooddisorders.The lattermay contribute to low
BMD by increasing cortisol levels [6, 7]. Medications used
to treat these conditions, including antiepileptics, antidepres-
sants, and antipsychotic medications, also have influences on
bone indices and vitaminDmetabolism [7–12]. Finally, child-
ren with ASD are often on proton pump inhibitors, which
may influence bone health by impairing insoluble calcium
absorption.
We have previously examined the relationship between
ASD and BMD in peripubertal boys [13]. In this study,
boys with ASD had lower BMD at the hip, femoral neck,
and lumbar spine compared to typically developing controls.
BMD was even lower in boys with ASD on a GFCF diet. In
a subsequent study that examined the prevalence of fractures
in children and adults with and without ASD using a national
database of emergency room visits, we found a higher odds
ratio for hip fractures in children and young adults (3–22
years) as well as older adults (23–50 years) with ASD than
those without ASD and a higher odds ratio for forearm and
spine fractures in women aged 23–50 years with ASD [14].
With the knowledge that childrenwithASDhavemultiple
risk factors for low BMD and with increasing evidence to
show that individuals with ASD may have low BMD and
increased risk of fractures, there is a compelling need to
determine how physicians are addressing the issue of bone
health in these children. Little is known about the prescribing
practice of vitamin D and calcium supplements in this
population or the practice of checking vitamin D levels in
this group, particularly in children on the GFCF diet, who
may be at higher risk.The primary objective of our study was
to review the calcium and vitamin D supplement prescribing
practices of physicians caring for children with ASD on a
GFCF diet. Our secondary objectives were to review the
practice of checking 25(OH)D and phosphorus levels in this
group and to describe the use ofmedications in these children
that may affect bone health.
2. Methods
2.1. Study Design and Subject Selection. This was a retrospec-
tive study of patients who presented to the Lurie Center for
Autism at the Massachusetts General Hospital for routine
clinic visits. The Lurie Center is a multidisciplinary clinical
and research center dedicated to the care of individuals
with autism spectrum disorders and other developmental
disorders.The Lurie Center Data Repository (LCDR) obtains
patient data via batched data transfer from the Partners
Research Patient Data Registry (RPDR) into a secure,
relational database, which is organized and queried using
the Structured Query Language (SQL) Server Management
Studio. Data available from the RPDR include patient
demographics, encounter billing data, diagnosis billing data,
outpatient clinical notes, and prescribed medications.
The patient population was identified by searching the
database for individuals who had encounters at MGH with a
billed diagnosis of ASD (“299” ICD-9 codes) when they were
between 3 and 25 years of age and had been seen at the Lurie
Center between 2004 and 2014, with a total of 2814 subjects
identified. All subjects met Diagnostic and Statistical Manual
of Mental Disorders (either IV or V) criteria for diagnosis
of an ASD. Clinical notes in the longitudinal medical record
for these patients were then reviewed for language referring
to the patient being on a gluten and/or casein-free diet (e.g.,
“gluten-free,” “casein-free,” “dairy-free,” and “gluten and
casein”). To do this, an SQL code was written that would
extract portions of note text surrounding occurrences of the
word “diet” which also contained the GFCF terms, excluding
notes with terms such as “not on a gluten-free” or “not on a
strict casein or gluten-free” diet. These clinical note extracts
were then reviewed by study staff to determinewhich patients
were on a dedicated GFCF diet. Using this strategy, a total
of 837 subjects were identified to be on a GFCF diet. We
excluded subjects who had a condition known to influence
bone health such as celiac disease, inflammatory bowel
disease, or renal disease. We then randomly selected 100
subjects for our study of whom 50 were on the GFCF diet and
50 were not. According to the Endocrine Society’s Clinical
Practice guidelines, we defined vitamin D deficiency as a
25(OH)D level below 20 ng/mL and vitamin D insufficiency
as a 25(OH)D level of 21–29 ng/mL [15].
This protocol was approved by the Partners Health Care
Institutional Review Board, and procedures used for data
collection were in compliance with the Health Insurance
Portability and Accountability Act (HIPAA). Due to the
retrospective nature of the study, and in accordance with
the guidelines of our Institutional Review Board, informed
consent and assent were not obtained.
2.2. Data Collection. We collected the following demo-
graphic data: age, sex, race, and self-reported ethnicity.
The clinical data that were collected included information
regarding vitaminD and calcium supplementation, 25(OH)D
and phosphorus levels, and use of antiepileptic, antipsychotic,
and antidepressant medications and proton pump inhibitors.
Information regarding Tanner stage of subjects was not
available because the clinical information was collected at
specialized neurodevelopmental visits. Similarly, subjects did
not have parathyroid hormone (PTH) levels measured.
To determine vitamin D and calcium supplementation
status, medication data was queried in the LCDR to find who
in the study population had been prescribed vitamin D or
calcium by their provider. Additionally, active and inactive
medication lists were reviewed in the electronic medical
record. Clinical notes were also queried using the same
text extraction method described above for notes containing
references to patients supplementing their diet with vitamin
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D or calcium, with or without a prescription from their pro-
vider.These note extracts were then reviewed by study staff to
confirm that subjects were on supplements. For the purpose
of our study, we counted the use of multivitamins towards
supplementation of both vitamin D and calcium. When we
surveyed some of the commonly used brands of children’s
multivitamins, we found that in general most brands tend
to have around 600 IU of vitamin D and around 100mg
of elemental calcium. To determine vitamin D and phos-
phorus levels, the laboratory results section of the subject’s
electronic medical record was reviewed. Also, clinical note
text extractionwas performed for notes containing references
to 25(OH)D and phosphorus level laboratory results with
subsequent confirmation done by study staff.The samemeth-
ods were used to determine the use of antiepileptic, antipsy-
chotic, and antidepressant medications, or proton pump
inhibitors in the study population.
2.3. Data Analysis. Data analysis was performed using JMP
statistical software version 11 (SAS Institute, Cary, NC). Anal-
yses were performed using Student’s 𝑡-test for continuous
variables and Pearson’s 𝜒2 test for categorical variables. A 𝑝
value of less than 0.05 was considered to be significant.
3. Results
The clinical characteristics of children with ASD on a GFCF
diet versus those not on a GFCF diet are summarized in
Table 1.The groups did not differ for demographic character-
istics, including age, sex, and self-reported ethnicity.
3.1. Vitamin D and Calcium Supplementation. Fifty-two per-
cent of the children on the GFCF diet were taking vitamin
D supplementation in comparison to 18% of those in the
non-GFCF group. Forty-six percent of subjects who were
on the GFCF diet were taking or prescribed calcium sup-
plementation in comparison with 14% in the non-GFCF
group (Figure 1). Compared to children on a non-GFCF diet,
children on the GFCF diet were more likely to be taking
vitamin D [OR 4.94, 95% CI (1.99–12.26), and 𝑝 = 0.0006]
and calcium supplements [OR 5.23, 95% CI (2.63–10.41), and
𝑝 < 0.0001].
3.2. 25(OH) Vitamin D Levels and Phosphorus Levels.
Twenty-four percent of children in the GFCF group had a
documented 25(OH)D level compared to none in the non-
GFCF group (Figure 2).Themean 25(OH)D level in children
on the GFCF diet was 41.4 ng/mL (SD 11.4). Of subjects on
the GFCF diet who had a 25(OH)D level checked, 92% had
a level greater than 30 ng/mL, the lower limit for sufficiency
as suggested by the Endocrine Society’s Clinical Practice
guidelines. Of the 24% of subjects on the GFCF diet with a
documented 25(OH)D level, 83% were taking a vitamin D
supplement (Figure 3). We further looked at the season in
which the 25(OH)D levels were measured and it is worthy
to note that the only two insufficient values were measured
in the winter months. We were unable to make a statistical
inference regarding seasonality because of our limited sample
size. The mean vitamin D level was higher in the GFCF
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Figure 1: Percentage of children on the GFCF diet versus the non-
GFCF diet taking vitamin D and calcium supplements.
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Figure 2: Percentage of subjects on the GFCF diet who had a
documented 25(OH)D level.
group that received supplementation (mean 42.8 ng/dL, SD
11.72) than in the group that did not (mean 32.5 ng/dL, SD
3.54). Sixteen percent of children on the GFCF diet had a
documented phosphorus level in comparison to 2% on the
non-GFCF diet. The mean phosphorus level when checked
was 5.4mg/dL (SD 1.0) in the GFCF group and 3.05mg/dL
(SD 0.5) in the non-GFCF group.
3.3. Medication Use. The use of antiepileptic, antipsychotic,
and antidepressant medication was similar between the two
groups. Some of themore commonly prescribed antiepileptic
medications were topiramate, valproic acid, lamotrigine, and
levetiracetam. The most commonly prescribed antipsychotic
medications included risperidone, quetiapine, and aripipra-
zole. Fluoxetine, sertraline, and citalopram were the most
commonly prescribed antidepressant medications. Children
in the GFCF group were more likely to be on a proton pump
inhibitor (𝑝 = 0.02).
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Table 1: Clinical characteristics of children on the GFCF diet versus those not on a GFCF diet.
Gluten-free, casein-free (GFCF) diet Non-GFCF diet 𝑝 value
Mean age in years (SD) 9.62 (4.66) 11.7 (4.66) 0.069
Sex (% male) 74 78 0.644
Self-reported ethnicity (%)
Non-Hispanic White: 66 Non-Hispanic White: 62
0.378
Hispanic: 2 Hispanic: 10
African American: 4 African American: 4
Asian: 16 Asian: 4
Other: 12 Other: 20
% on vitamin D supplements 52 18 <0.001
% on calcium supplements 46 14 <0.001
% with documented 25(OH)D level 24 0 0.001
Mean 25(OH)D level in ng/mL (SD) 41.4 (11.4) N/A N/A
% with documented phosphorus level 16 2 0.013
Mean phosphorus level in mg/dL (SD) 5.4 (1.0) 3.05 (0.5) 0.062
% on antiepileptic drugs 14 22 0.303
% on antipsychotics 14 28 0.087
% on antidepressants 18 32 0.108
% on proton pump inhibitors 30 8 0.002
92%
8% 0%
Sufficient 25D level
Insufficient 25D level
Deficient 25D level
Figure 3: Proportion of subjects on theGFCFdiet with documented
25(OH)D levels, with sufficient levels. In accordance with the
Endocrine Society Practice guidelines [15], a sufficient level was
considered to be ≥30 ng/mL, an insufficient level was considered to
be between 21 and 29 ng/mL, and a deficient level was considered to
be ≤20 ng/dL.
4. Discussion
Our results suggest that, in both groups, a large proportion of
subjects were not supplemented with calcium or vitamin D.
Children who were on the GFCF diet were more likely to be
supplemented with calcium and vitamin D than those not on
the diet. However, even in the GFCF group, approximately
50% of the subjects did not receive supplementation with
either nutrient. As stated earlier, for the purpose of this
study, we counted the use of multivitamins towards both
vitamin D and calcium supplementation as most children’s
multivitamins contain vitamin D and many contain calcium.
Therefore, our results may even be an overestimate of the
actual proportion of children with ASD receiving supple-
ments.
Our results also indicate that only a small proportion
of children on the GFCF diet and none on the non-
GFCF diet had vitamin D levels checked, even when on
multiple medications that could potentially affect vitamin D
metabolism and bone health. Of note, a large proportion of
the vitamin D levels that were checked were above 30 ng/mL,
the recommended lower limit for sufficient levels according
to the Clinical Practice guidelines of the Endocrine Society
[15]. This suggests that those providers who were checking
levels were also supplementing their patients with vitamin
D, leading to sufficient levels in these children. Of note,
serum phosphate levels may decrease slightly following an
oral glucose load [16], a phenomenon that is thought to
be mediated through insulin. However, we do not believe
that this would significantly confound the serum phosphate
results and clinically do not require patients to be fasting
when measuring serum phosphorus levels.
Regardingmedication usage, both groups of subjectswere
on multiple medications that could potentially affect bone
health. Antiepileptic drugs such as phenytoin, primidone,
carbamazepine, oxcarbazepine, ethosuximide, and pheno-
barbital induce the cytochrome p450 enzyme system. This
induction leads to increased catabolism of vitamin D to
inactivemetabolites and a subsequent rise in parathyroid hor-
mone (PTH) levels. The rise in PTH increases mobilization
of calcium from bone and thereby modifies bone turnover
[8]. In contrast, sodium valproate inhibits the cytochrome
p450 system, and its use is also associated with abnormal bio-
chemical indices of bone and mineral metabolism, bone loss,
and higher fracture rates in adults and children [7, 9]. Few
studies have examined the newer antiepilepticmedications in
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relation to vitamin D and bone metabolism and fracture risk.
The use of lamotrigine, increasingly common in children,
is associated with lower BMD and higher markers of bone
turnover compared to children not receiving antiepileptic
medications [10]. Furthermore, atypical antipsychotics may
impact bone by increasing prolactin secretion and causing
hypogonadism [11]. Both tricyclic antidepressants and selec-
tive serotonin reuptake inhibitors are associated with an
increased risk of fragility fractures in observational studies
in adults [12]. Whether the effects of these medications on
fractures are from direct effects of these drugs on bone or
from indirect effects related to sedation and falls needs fur-
ther investigation. A longitudinal study of 96 boys between
the ages of 7 and 17 years showed that chronic SSRI treatment
in children was associated with reduced but stable bone mass
for age, while chronic risperidone treatment was associated
with failure to accrue bone mass [17]. Drugs such as proton
pump inhibitors (PPIs) that reduce gastric acid secretionmay
decrease calcium absorption because insoluble calcium such
as in calcium carbonate requires an acidic environment for
absorption. Whether PPI use is associated with increased
fracture risk is yet to be definitively established.
To our knowledge, this is one of the first studies evaluating
the prescribing practices of calcium and vitamin D by
providers caring for children with ASD and the practice of
checking vitamin D levels in these children. Stewart et al.
in 2015 reported the results of a cross-sectional study in 288
childrenwithASD that examined dietary supplement use and
micronutrient intake. A GFCF diet was consumed by 12% of
participants.Their results showed that even after supplemen-
tation, about 50%of childrenwithASDhad inadequate intake
of calcium, and about 30% had inadequate intake of vitamin
D. Similar to our results, their study showed that children on
the GFCF diet were more likely to be on supplements [18].
One of the strengths of our study is that it was conducted
in a specialized tertiary care outpatient center with access to a
large number of patients with ASD on the GFCF diet.The use
of the electronic medical record and SQL code to extract text
for keywords ensured that a thorough chart review was com-
pleted. This study also has limitations that are inherent to a
retrospective chart review.One such limitation is thatwewere
unable to quantify the duration of exposure of subjects to the
GFCF diet. However, because we looked at whether subjects
were ever on vitamin D and calcium supplementation at our
center, we likely also covered the period that they were on the
GFCF diet. Another limitation is that parents may not have
reportedmedication use, especially over the counter vitamins
and supplements, and providers may not have accurately
documented medications especially when considering drugs
such as multivitamins or supplements.
5. Conclusions
This study highlights a significant gap in the practice of
prescribing vitamin D and calcium supplements in children
with ASD and the practice of checking vitamin D and phos-
phorus levels in this group. Children with ASD have several
risk factors that may affect BMD that providers caring for
these children need to be aware of. Given that the childhood
years are critical for bone accrual, we believe that children
with ASD should be screened for vitamin D status with
25(OH)D levels and serum phosphorus levels and assessed
for vitamin D and calcium intake. Supplementation should
be implemented based on clinical judgment after evaluation
of risk factors. This is particularly necessary in children on
restrictive diets such as the GFCF diet and those on med-
ications that can have adverse effects on bone. Prospective
studies are needed to examine the effects of the GFCF diet
on bone health and incidence of fractures in individuals with
ASD and the impact of supplementation on these endpoints.
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